Seth Blackley Buys 55,225 Shares of Evolent Health, Inc. (NYSE:EVH) Stock

Evolent Health, Inc. (NYSE:EVH - Get Free Report) CEO Seth Blackley purchased 55,225 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was bought at an average cost of $9.01 per share, with a total value of $497,577.25. Following the acquisition, the chief executive officer now owns 762,217 shares of the company's stock, valued at approximately $6,867,575.17. The trade was a 7.81 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Evolent Health Price Performance

NYSE EVH traded up $0.03 during trading hours on Thursday, reaching $9.51. The company's stock had a trading volume of 2,112,922 shares, compared to its average volume of 2,076,186. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -11.59 and a beta of 1.49. The company's 50-day moving average is $10.26 and its two-hundred day moving average is $17.23. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. Evolent Health, Inc. has a 1-year low of $8.35 and a 1-year high of $34.07.

Evolent Health (NYSE:EVH - Get Free Report) last announced its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The business had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. On average, equities analysts predict that Evolent Health, Inc. will post 0.08 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Evolent Health during the fourth quarter valued at approximately $26,000. R Squared Ltd acquired a new position in Evolent Health in the 4th quarter valued at $31,000. AlphaQuest LLC lifted its holdings in Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after purchasing an additional 3,031 shares in the last quarter. Covestor Ltd lifted its holdings in Evolent Health by 138.1% in the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Evolent Health by 90.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after purchasing an additional 2,358 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on EVH. Needham & Company LLC reissued a "buy" rating and issued a $15.00 price objective on shares of Evolent Health in a report on Friday, February 21st. JPMorgan Chase & Co. cut their price target on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a report on Monday. Truist Financial decreased their price objective on shares of Evolent Health from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Wednesday, January 22nd. Stephens dropped their price objective on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a report on Tuesday, January 21st. Finally, Oppenheimer reduced their target price on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a report on Friday, January 24th. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $17.71.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.